Can a simple shunt help liver cancer patients live longer?
NCT ID NCT07365930
Summary
This study is observing whether adding a TIPS procedure—a small shunt placed in the liver to reduce pressure—helps patients with advanced liver cancer better tolerate their standard immunotherapy drugs (atezolizumab and bevacizumab). Researchers will follow 350 patients in Germany to see if this combination helps preserve liver function, reduces complications, and improves survival and quality of life. The goal is to gather real-world evidence to help doctors personalize treatment plans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital of Düsseldorf
RECRUITINGDüsseldorf, North Rhine-Westphalia, 40225, Germany
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.